A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Latest Information Update: 25 May 2025
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Doxorubicin; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms ASCENT-GYN-01
- Sponsors Gilead Sciences
Most Recent Events
- 17 Jul 2024 New trial record